The drugmaker shed value after it told investors that widening Journavx’s approval to chronic pain wouldn’t be as straightforward as hoped.Vertex Pharmaceuticals made its name and fortune by developing ever more effective medicines for the rare disease cystic fibrosis. On Monday, the biotechnology company disclosed two setbacks that suggest one of its next targets for […]
